Investors / United States / SymBiosis Capital Management
SymBiosis Capital Management
Venture capital · AR, United States · North America
SymBiosis Capital Management is a biotechnology venture capital firm based in Arkansas. It partners with companies developing therapeutics for life-threatening diseases with objective, approvable endpoints.
Invests inHealthcare & Biotech
In its own wordsbiotechnologytherapeuticslife sciencesdrug discoverymanufacturing
Your fit with SymBiosis Capital Management
Four questions about your startup
See how your round matches what it backs, point by point.
Or find every investor that fitsSymBiosis Capital Management lists 29 checked portfolio companies on its own site and is named in 7 funding rounds, 1 of them as lead. Its most frequent entry is Series B, 60% of the companies with a known first round. Its largest theme is Healthcare & Biotech (100%). 81% of its companies are based in United States. It invests most often alongside RA Capital, Catalio Capital Management and 5AM Ventures.
Counts come from funding rounds that name SymBiosis Capital Management, complete from mid-2025: earlier rounds appear only when they were reported later. Round amounts and full round histories are on Fundup AI.
Round figures show recent activity, not SymBiosis Capital Management's whole history. Rounds on record name 7 companies; its own site lists 29. Funding rounds are complete from mid-2025, so counts and the yearly trend undercount a firm that invested before then. The portfolio, themes and places come from its own site and are not affected.
Entry stage
share of companies by the stage of its first roundSymBiosis Capital Management does not state its stages on its site, so only what it does is shown.
Show as a table
| Value | |
|---|---|
| Pre-seed | 0% |
| Seed | 0% |
| Series A | 0% |
| Series B | 60% |
| Growth | 40% |
Activity by year
rounds it joined, last 10 yearsShow as a table
| Total | Rounds it led | |
|---|---|---|
| '17 | 0 | 0 |
| '18 | 0 | 0 |
| '19 | 0 | 0 |
| '20 | 0 | 0 |
| '21 | 0 | 0 |
| '22 | 0 | 0 |
| '23 | 0 | 0 |
| '24 | 0 | 0 |
| '25 | 4 | 0 |
| '26 | 3 | 1 |
Investor profile
percentile among all firmsShow as a table
| Measure | Percentile of all firms | Value |
|---|---|---|
| Portfolio size | 65th | 28 companies |
| Recent activity | 86th | 5 rounds in 12 months |
| Early stage | 54th | 0% of entries at pre-seed or seed |
| Evidence | 93th | 21% of companies confirmed by a round |
| Sector focus | 100th | 100% in its largest sector |
| Reach | 78th | 5 countries |
Invests most often with
firms sharing its portfolio companiesShow as a table
| Share | |
|---|---|
| RA Capital | 8 |
| Catalio Capital Management | 5 |
| 5AM Ventures | 3 |
| ARCH Venture Partners | 3 |
| Abingworth | 3 |
| F-Prime Capital | 3 |
| Osage University Partners | 3 |
| B Capital | 2 |
Its portfolio companies
where they are based, and what their own sites showSite status
- Site answers2897%
- No longer answers00%
- Points to another company13%
- Parked or sold domain00%
A site that stops answering three checks in a row is counted as no longer answering; that is not proof of closure. A site that points to another company is often an acquisition.
Investment themes
share of its checked companiesThis firmAll checked companies
Show as a table
| This firm | All checked companies | |
|---|---|---|
| Healthcare & Biotech | 100% | 15% |
Co-investor network
who it backs companies with, and who they back togetherCompare SymBiosis Capital Management head to head
portfolio size, rounds, entry stages, themes and the companies both backThree or more firms at once: portfolio overlap.
Recent portfolio activity
when companies last raised with SymBiosis Capital Management| Date | Company | Stage |
|---|---|---|
| 15 Jul 2026 | Series C+ | |
| 7 Jul 2026 | Series C+ Led | |
| 10 Jun 2026 | Series B | |
| 16 Dec 2025 | Series B | |
| 17 Nov 2025 | Round | |
| 22 Sept 2025 | Round |
Round details for SymBiosis Capital Management
Amounts, full round histories and every co-investor in SymBiosis Capital Management's rounds are on Fundup AI. VCinfo covers investors and their portfolios.
Portfolio
29 companies checked against their own sites| Company | What it does | Themes | First round with it | Evidence |
|---|---|---|---|---|
| AdvanCell is a clinical-stage radiopharmaceutical company developing targeted alpha therapies for cancer treatment. | Healthcare & Biotech | Jul 2026Series C+ | Page + round | |
| Aeovian Pharmaceuticals develops small molecules to treat certain rare genetic and age-related diseases | Healthcare & Biotech | Dec 2025Series B | Page + round | |
| Alebund is a biopharmaceutical company focused on developing innovative treatments for kidney diseases and related chronic diseases. | Healthcare & Biotech | Portfolio page | ||
| Attivare Therapeutics develops personalized cancer immunotherapy treatments using artificial intelligence and biomaterials | Healthcare & Biotech | Portfolio page | ||
| The company is developing an investigational drug candidate for osteoarthritis. | Healthcare & Biotech | Portfolio page | ||
| The company is a clinical-stage biopharmaceutical company dedicated to revolutionizing the treatment of neurodegenerative diseases to restore and protect neuronal health and function. | Healthcare & Biotech | Portfolio page | ||
| Portfolio page | ||||
| eGenesis develops human-compatible organs for patients with organ failure using genome engineering and transplantation | Healthcare & Biotech | Portfolio page | ||
| Endeavor BioMedicines is a clinical-stage biotechnology company focused on developing medicines for the treatment of fibrotic diseases with high unmet need. | Healthcare & Biotech | Portfolio page | ||
| Ensoma is an in vivo hematopoietic stem cell engineering company that creates a new kind of genomic medicine for patients around the world. | Healthcare & Biotech | Sept 2025Round | Page + round | |
| Evommune discovers and develops innovative therapies that target key drivers of chronic inflammatory disease. | Healthcare & Biotech | Portfolio page | ||
| F2G develops therapeutics for rare fungal infections | Healthcare & Biotech | Portfolio page | ||
| Fore Biotherapeutics develops targeted therapies for treating cancers. | Healthcare & Biotech | Jul 2026Series C+ | Page + round | |
| The company develops mRNA therapeutics and in vivo cell therapies for cancer and auto-immune diseases | Healthcare & Biotech | Portfolio page | ||
| The company develops a machine learning-based platform to predict how tumors respond to drugs | Healthcare & Biotech | Portfolio page | ||
| Portfolio page | ||||
| Parabilis Medicines develops peptide therapeutics to treat serious diseases, including cancer. | Healthcare & Biotech | Portfolio page | ||
| Paradox Immunotherapeutics develops specialized antibodies to selectively target problematic proteins that cause protein misfolding diseases | Healthcare & Biotech | Portfolio page | ||
| R1 Therapeutics is developing innovative first-in-class therapies for patients with kidney disease, starting with lead asset AP306 for the treatment of hyperphosphatemia in patients with chronic kidney disease. | Healthcare & Biotech | Portfolio page | ||
| Recursion discovers and develops medicines using artificial intelligence | Healthcare & Biotech | Portfolio page |
About this data
site last read 5 Nov 2026- Site
- symbiosis.vc
- Last read
- 5 Nov 2026
- Watching since
- 6 Nov 2026
- Rounds since
- 22 Sept 2025
- Companies checked
- 29
Rates come from what VCinfo has observed since observation_start. Firms tend to remove companies that closed, so early rates understate reality. A company leaving a portfolio page does not mean it closed or exited. An unreachable site means our checks failed, nothing more.
Get SymBiosis Capital Management's profile as data
Pull SymBiosis Capital Management's portfolio, co-investors and changes through one API key or MCP, open every portfolio row, compare it with other firms, and get an email when it adds a company or files a fund.
Work email, sign-in link by email. Already have an account? Log in- Ask AI5 plain-English investor searches a day
- Full listsEvery portfolio row and two-firm overlap
- API and MCP100 REST or MCP calls a month, one key
- AlertsFollow 5 investors for portfolio and fund changes
$ curl -H "X-API-Key: YOUR_KEY" \
https://api.vcinfo.io/v1/firms/symbiosis.vc
# also
GET /v1/firms/symbiosis.vc/portfolio
GET /v1/firms/symbiosis.vc/coinvestors
GET /v1/firms/symbiosis.vc/news